Cite
Hoeksema KA, Jayanthan A, Cooper T, et al. Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Onco Targets Ther. 2011;4:149-68doi: 10.2147/OTT.S21553.
Hoeksema, K. A., Jayanthan, A., Cooper, T., Gore, L., Trippett, T., Boklan, J., Arceci, R. J., & Narendran, A. (2011). Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. OncoTargets and therapy, 4149-68. https://doi.org/10.2147/OTT.S21553
Hoeksema, Kimberley A, et al. "Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia." OncoTargets and therapy vol. 4 (2011): 149-68. doi: https://doi.org/10.2147/OTT.S21553
Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A. Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Onco Targets Ther. 2011;4:149-68. doi: 10.2147/OTT.S21553. Epub 2011 Sep 05. PMID: 21949608; PMCID: PMC3176174.
Copy
Download .nbib